Skip to main content

Table 4 Adverse events related to camrelizumab administration in the TACE-Camrelizumab group

From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

Adverse Event All Events CTCAE Grade
1 2  ≥ 3
RCCEP 14 (70.0%) 10 (50.0%) 4 (20.0%) 0 (0%)
Asthenia 4 (20.0%) 4(20.0%) 0 (0%) 0 (0%)
Rash 4 (20.0%) 4 (20.0%) 0(0%) 0 (0%)
Hypothyroidism 2 (10.0%) 2 (10.0%) 0 (0%) 0 (0%)
Pneumonitis 1 (5.0%) 1 (5.0%) 0 (0%) 0 (0%)
  1. CTCAE Common Terminology Criteria for Adverse Events, RCCEP Reactive cutaneous capillary endothelial proliferation